(SLGL) Sol-Gel Technologies Ltd. Marketing Mix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(SLGL) Sol-Gel Technologies Ltd. Complete Analysis Pack
Download Your Competitive Advantage
This Sol-Gel Technologies Ltd. 4P's Marketing Mix Analysis explains the company’s product offering, target pricing, distribution channels, and promotional tactics in a concise, actionable format; the page shows a genuine preview/sample of the analysis so you can evaluate style and substance before buying. Purchase the full version to receive the complete ready-to-use report.
Product
Twyneo acne cream
Twyneo is a once-daily, non-antibiotic prescription cream for acne vulgaris, built on Sol-Gel Technologies Ltd.’s microencapsulation platform. Its launch followed 2 Phase III trials, giving the product a clear clinical base before commercialization. In the 4P mix, that supports premium pricing and dermatologist-led prescribing, not OTC volume.
Epsolay rosacea cream
Epsolay is a once-daily prescription cream for papulopustular rosacea, built on Sol-Gel Technologies Ltd.'s microencapsulation platform. The product completed Phase III development and later won U.S. FDA approval in 2023, giving Sol-Gel a second dermatology asset beside Twyneo. For the 4P's mix, its niche, high-discipline use supports premium pricing and specialist-led promotion.
SGT-210 palmoplantar keratoderma
SGT-210 is Sol-Gel Technologies Ltd.’s Phase I candidate for palmoplantar keratoderma, a rare skin disorder that affects roughly 1 in 100,000 people. It broadens Sol-Gel beyond acne and rosacea into orphan dermatology, where small patient pools can support premium pricing and faster development paths. For Product, it adds a new pipeline asset with high unmet need and clear differentiation potential.
Psoriasis pipeline assets
Sol-Gel Technologies Ltd. is building a psoriasis pipeline around 3 assets: erlotinib, tapinarof, and roflumilast. Psoriasis affects about 125 million people worldwide, so even small share gains can matter. The focus also extends beyond psoriasis to other skin conditions, which widens the dermatology reach.
- 3 pipeline assets under review
- Psoriasis plus broader skin uses
- Targets a 125 million-patient market
Generic topical dermatology
Sol-Gel Technologies Ltd. also sells generic topical dermatology, which lowers launch risk versus branded drugs and gives the product mix a steadier base. In FY2025, this helps balance higher-margin proprietary skin treatments with non-branded products that can face faster price pressure.
- Lower-risk, non-branded revenue stream
- Balances proprietary skin therapies
- Supports broader dermatologist reach
For the 4P mix, this line strengthens Product depth and Price flexibility, while also widening access in routine skin care. It fits Sol-Gel's dual model: innovation-led branded assets plus generic topical medicines.
Sol-Gel’s Dermatology Mix Balances Growth, Differentiation, and Pipeline Depth
Sol-Gel Technologies Ltd.’s Product mix is centered on branded dermatology: Twyneo for acne, Epsolay for papulopustular rosacea, and SGT-210 for a rare skin disorder. The pipeline also adds psoriasis assets and generic topicals, so the range spans premium, specialist-led drugs and lower-risk revenue. That gives the mix depth, clinical differentiation, and pricing flexibility.
| Asset | Status | Use |
|---|---|---|
| Twyneo | Commercial | Acne |
| Epsolay | FDA approved | Rosacea |
| SGT-210 | Phase I | Rare dermatosis |
What is included in the product
Detailed Word Document
Provides a company-specific 4P’s analysis of Sol-Gel Technologies Ltd.’s product, pricing, place, and promotion strategy.
Editable Excel File
Condenses Sol-Gel Technologies Ltd.’s 4Ps into a quick, easy-to-grasp view that reduces analysis time and supports faster decisions.
Reference Sources
Lists primary, reputable sources linking each key claim to traceable industry reports, datasets, and benchmarks to speed due diligence and verify assumptions.
Place
Ness Ziona headquarters
Sol-Gel Technologies Ltd. is headquartered in Ness Ziona, Israel, its main corporate base and the center of strategic management and core operations. The city gives the Company direct access to Israel’s biotech cluster and talent pool, which supports R&D and business execution. In 2025, Sol-Gel reported a market cap near $50 million, so a lean HQ matters for cost control and speed.
Israel-centered development
Sol-Gel Technologies Ltd. centers its primary development work in Ness Ziona, Israel, where its technology, research, and clinical planning are based. That Israel hub keeps its dermatology R&D tightly focused and easier to manage. The setup supports faster coordination across formulation, trial design, and regulatory work.
Clinical trial network
Sol-Gel Technologies Ltd. relies on external clinical sites for Phase I and Phase III work, so its clinical trial network is a key access point to patients and investigators. These sites let the Company test its products in real-world research settings across multiple locations, which helps support safety, efficacy, and regulatory approval. Faster patient enrollment matters because trial delays can slow development and raise costs.
Partner-led commercialization
Sol-Gel Technologies Ltd. uses partner-led commercialization to widen reach without building a large sales force. Its Perrigo tie-up helps sell products beyond internal operations, so distribution is not limited to Israel. The model now covers 2 FDA-approved dermatology products, EPSOLAY and TWYNEO, through external commercial channels.
- Extends reach through Perrigo
- Reduces reliance on in-house sales
- Expands access beyond Israel
Prescription dermatology channels
Sol-Gel Technologies Ltd. sells finished products through prescription medicine channels, so access runs through healthcare professionals and pharmacy systems. This place strategy keeps distribution inside regulated drug routes and supports controlled prescribing and dispensing.
That matters because prescription channels shape reach, refill flow, and payer access for a dermatology brand. The company does not rely on open retail selling; it depends on physician adoption and pharmacy fulfillment in the U.S. market.
- Prescription-only access through doctors.
- Dispensed via pharmacy systems.
- Distribution stays tightly regulated.
- Channel use depends on reimbursement.
Sol-Gel’s Lean Footprint Supports Its Small-Scale U.S. Reach
Sol-Gel Technologies Ltd. keeps Place lean: R&D and control sit in Ness Ziona, Israel, while U.S. access runs through external clinical sites and partner-led pharmacy channels. In 2025, the Company had about a $50 million market cap, so this low-fixed-cost footprint fits its small scale.
| Place factor | Data |
|---|---|
| HQ | Ness Ziona, Israel |
| Commercial reach | Perrigo-led U.S. distribution |
| Approved products | 2 FDA products in 2025 |
Preview Before You Purchase
Sol-Gel Technologies Ltd. Reference Sources
The preview shown here is the actual Sol-Gel Technologies Ltd. 4P's Marketing Mix analysis you’ll receive instantly after purchase—complete, editable, and ready to use with no surprises.
Promotion
Phase III results
Sol-Gel uses Phase III results as a strong promotion signal. Twyneo and Epsolay both cleared Phase III, with Twyneo showing statistically significant acne clearance in pivotal trials and Epsolay meeting its rosacea endpoints. Positive late-stage data helps drive prescriber awareness, partner interest, and investor confidence.
Regulatory milestones
FDA milestones are the core of Sol-Gel Technologies Ltd. promotion, because U.S. approvals for TWYNEO in 2021 and EPSOLAY in 2022 give the brand real regulatory proof. Those wins matter in dermatology, where safety and efficacy data drive trust and adoption. Each new FDA update can strengthen prescriber confidence and support wider product use.
Partner announcements
Partner announcements are a key promotion tool for Sol-Gel Technologies Ltd., because they show the market that the Company can work with established commercial partners instead of relying on broad consumer ads. The Perrigo relationship signals real launch and distribution capability for EPSOLAY and TWYNEO, which helps build trust with investors, physicians, and retailers. These updates lift visibility at low cost and can support partner-led sales momentum.
Scientific communications
Sol-Gel Technologies Ltd. uses scientific communications to reach dermatologists and industry stakeholders, which fits a clinical-stage model where trial updates and data readouts matter most. In 2025, the company reported net product sales of $13.4 million and R&D expense of $10.2 million, so congress activity and medical disclosures help keep pipeline credibility in view.
- Targets physicians, not mass buyers
- Uses trial updates and congress data
- Supports pipeline trust with disclosures
- Best for clinical-stage dermatology brands
Investor relations
Investor relations is Sol-Gel Technologies Ltd.'s main promotion tool, because a development-stage biotech depends on clear updates to keep investors engaged. In 2025/2026, earnings releases, pipeline milestones, and corporate decks help explain cash use, R&D spend, and program timing, which can move valuation fast. One clean rule: if the market cannot track the science, it prices more risk.
- Use earnings updates to guide expectations.
- Share pipeline news on time.
- Back claims with cash and R&D data.
- Keep investors informed between results.
FDA-backed growth: Sol-Gel’s approvals, sales, and R&D signal execution
Sol-Gel Technologies Ltd. promotes through FDA proof, partner news, and medical congress data. TWYNEO and EPSOLAY approvals in 2021 and 2022 give the brand strong clinical credibility, while 2025 net product sales of $13.4 million and R&D of $10.2 million keep investor updates tied to real execution.
| Promo lever | Key data |
|---|---|
| Regulatory | TWYNEO 2021; EPSOLAY 2022 |
| Financial | 2025 sales $13.4M; R&D $10.2M |
Price
Prescription branded pricing
Sol-Gel Technologies Ltd.'s Twyneo and Epsolay are prescription dermatology brands, so pricing sits above generics because the value comes from convenience, proprietary formulations, and clinical differentiation. In branded Rx, patients and payers often pay a premium for one-step acne and rosacea treatment, not just the active ingredient.
Partner-set market pricing
Sol-Gel Technologies Ltd. uses partner-set market pricing because Perrigo helps commercialize products, so price points can be tied to shared access and channel goals. This is common in licensed launches, where the partner controls part of the go-to-market plan. In 2025, Perrigo generated about $4 billion in annual sales, showing the scale of the retail channels that can shape pricing.
Reimbursement access
Reimbursement access is a key pricing lever for Sol-Gel Technologies Ltd. because pharmacy benefit managers manage more than 80% of U.S. prescriptions, so payer coverage can decide uptake faster than list price.
Dermatology drugs often need formulary placement and prior-approval ease to win fills, and net realized price can land well below list after rebates and discounts.
So, for Sol-Gel Technologies Ltd., price acceptance depends less on sticker price and more on pharmacy benefit access and payer tiering.
Generic product pricing
Sol-Gel Technologies Ltd.'s generic topical dermatology products are priced for cost-sensitive buyers, where generic drugs usually launch well below branded products and win share on lower out-of-pocket cost. That pricing tier helps Sol-Gel serve high-volume demand, while its branded pipeline aims for higher pricing and margin potential.
Generic line: lower price, higher access
Branded pipeline: higher price, higher margin
Price mix: volume-led, value-led split
Pipeline not yet fully priced
SGT-210 and Sol-Gel Technologies Ltd.'s other investigational assets are still in development, so there is no stable commercial price yet. Clinical-stage drugs usually get priced only after approval, and the final tag will depend on the target indication, competing therapies, and payer reimbursement. In biotech, that means today’s price is still a pipeline option, not a market rate.
- SGT-210 is not yet approved
- No commercial price is set
- Pricing will hinge on payers
Sol-Gel’s Pricing Hinges on Payers, Not Sticker Price
Sol-Gel Technologies Ltd. prices Twyneo and Epsolay as premium branded Rx products, so access and payer tiering matter more than sticker price. Perrigo’s 2025 sales were about $4.0 billion, showing the channel scale behind partner-led pricing. Generic dermatology lines stay lower-priced to drive volume, while SGT-210 has no set commercial price yet.
| Item | Price signal | 2025/2026 data |
|---|---|---|
| Twyneo, Epsolay | Premium Rx | Payer-led |
| Perrigo | Channel scale | $4.0B sales |
| SGT-210 | No market price | Not approved |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.